Advertisement

Topics

PubMed Journals Articles About "Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia" RSS

06:51 EST 17th December 2017 | BioPortfolio

Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia articles that have been published worldwide.

More Information about "Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia" on BioPortfolio

We have published hundreds of Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia news stories on BioPortfolio along with dozens of Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia Clinical Trials and PubMed Articles about Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia Companies in our database. You can also find out about relevant Genehmigt Erweiterte Indikation Novartis Krebsmittel Zykadia Drugs and Medications on this site too.

Showing "genehmigt erweiterte Indikation Novartis Krebsmittel Zykadia" PubMed Articles, all 11

Erfahrungen am Lebensende: Eine Umfrage bei Ärzten und Pflegenden eines Spitals für anthroposophisch erweiterte Medizin.


Google, Novartis back Medicxi's ambitions.

First approval in sight for Novartis' CAR-T therapy after panel vote.


Novartis trial validates inflammasome as chronic disease driver.

Patent trend and competitive analysis of cancer immunotherapy in the United States.

Immunotherapy has brought high hopes for cancer treatment, and attracted tremendous resources from the biopharmaceutical community. Here we analyze cancer immunotherapy-related patents granted by the United States Patent and Trademark Office in the past decade (2006-2016). A total of 2,229 patents were identified in 13 subfields. The growth of patent number in this field has outpaced the background rate, with cytokine-related therapies, immune checkpoint inhibitors, and natural killer cell therapies growing...

Letter--The Authors Respond.

None of the authors of this study are involved in financial or personal relationships with agencies, institutions, or organizations that inappropriately influenced the statistical analysis plan or interpretation of the study results. DiDomenico received an honorarium from Amgen for the preparation of a heart failure drug monograph for Pharmacy Practice News and was a coinvestigator on funded research for the Patient-Centered Outcomes Research Institute. DiDomenico also serves as an advisory board member for...

Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory Medicine.

When faced with a diagnosis of multiple sclerosis (MS), patients often turn to the Internet and social media to find support groups, read about the experiences of other people affected by MS and seek their advice, and research their condition and treatment options to discuss with their healthcare professionals (HCPs). Here, we examine the use of social media and the Internet among patients with MS, considering its impact on patient empowerment and patient participation in treatment decision-making and MS re...

Ethics approval in applications for open-access clinical trial data: An analysis of researcher statements to clinicalstudydatarequest.com.

Although there are a number of online platforms for patient-level clinical trial data sharing from industry sponsors, they are not very harmonized regarding the role of local ethics approval in the research proposal review process. The first and largest of these platforms is ClinicalStudyDataRequest.com (CSDR), which includes over three thousand trials from thirteen sponsors including GlaxoSmithKline, Novartis, Roche, Sanofi, and Bayer. CSDR asks applicants to state whether they have received ethics approva...

Neue Laser und Strahlquellen - alte und neue Risiken?

Die Entwicklungen im Bereich dermatologischer Laser, hochenergetischer Blitzlampen, LED und neuer Energie- und Strahlquellen der letzten Jahre haben gezeigt, dass mit neuen Wellenlängen, Konzepten und Kombinationen zusätzliche, zum Teil über den ästhetischen Bereich hinaus gehende therapeutische Optionen für den Dermatologen erschlossen werden konnten. Wurden bisher zum Beispiel mit fraktionalen Lasern Falten behandelt, sind eben diese Systeme heute in Kombination mit Medikamenten wichtige Werkzeuge be...

Establishment of a cohort for deep phenotyping of the immune response to influenza vaccination among elderly individuals recruited from the general population.

Elderly individuals have the highest burden of disease from influenza infection but also the lowest immune response to influenza vaccination. A better understanding of the host response to influenza vaccination in the elderly is therefore urgently needed. We conducted a biphasic prospective, population-based study from Dec. 2014 to May 2015 (pilot study) and Sept. 2015 to May 2016 (main study). Individuals 65-80 y of age were randomly selected from the residents' registration office in Hannover, Germany, fo...

Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study).

PurposeOur aim was to evaluate the impact of intravitreal ranibizumab pretreatment on the outcome of vitrectomy surgery for advanced proliferative diabetic retinopathy. The objective was to determine the feasibility of a subsequent definitive trial and estimate the effect size and variability of the outcome measure.Patients and methodsWe performed a pilot randomised double-masked single-centre clinical trial in 30 participants with tractional retinal detachment associated with proliferative diabetic retinop...


Quick Search
Advertisement